Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation

ABSTRACT Combination of oncolytic virotherapy with immunomodulators is emerging as a promising therapeutic strategy for numerous tumor entities. In this study, we developed measles Schwarz vaccine strain vectors encoding immunomodulators to support different phases in the establishment of antitumor immune responses. Therapeutic efficacy of the novel vectors was evaluated in the immunocompetent MC38cea tumor model. We identified vectors encoding an IL-12 fusion protein (MeVac FmIL-12) and an antibody against PD-L1 (MeVac anti-PD-L1), respectively, as the most effective. Treatment of established tumors with MeVac FmIL-12 achieved 90% complete remissions. Profiling of the tumor immune microenvironment revealed activation of a type 1 T helper cell-directed response, with MeVac FmIL-12 ensuring potent early natural killer and effector T cell activation as well as upregulation of the effector cytokines IFN-γ and TNF-α. CD8+ T cells were found to be essential for the therapeutic efficacy of MeVac FmIL-12. Results of this study present MeVac FmIL-12 as a novel approach for targeted IL-12 delivery and elucidate mechanisms of successful immunovirotherapy.

[1]  H. Kaufman,et al.  Erratum: Oncolytic viruses: a new class of immunotherapy drugs , 2016, Nature Reviews Drug Discovery.

[2]  Michael R. Speicher,et al.  The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis , 2016, Science Translational Medicine.

[3]  L. Zitvogel,et al.  Trial Watch—Oncolytic viruses and cancer therapy , 2016, Oncoimmunology.

[4]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. von Kalle,et al.  CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[7]  G. McFadden,et al.  Viruses for tumor therapy. , 2014, Cell host & microbe.

[8]  T. Giese,et al.  Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer , 2014, Journal of Virology.

[9]  K. Tamada,et al.  Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1–Mediated Immune Suppression , 2013, The Journal of Immunology.

[10]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[11]  C. von Kalle,et al.  Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. , 2013, Human gene therapy.

[12]  L. Zitvogel,et al.  Trial Watch-Oncolytic viruses and cancer therapy. , 2016 .

[13]  F. Tangy,et al.  Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells , 2013, Clinical Cancer Research.

[14]  Y. Nakanishi,et al.  Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. , 2012, Cancer research.

[15]  A. Eliopoulos,et al.  Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. , 2012, Cancer research.

[16]  P. Coffer,et al.  Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. , 2012, Blood.

[17]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[18]  J. Bond,et al.  Measles virus causes immunogenic cell death in human melanoma , 2011, Gene Therapy.

[19]  J. Prieto,et al.  Successful Colon Cancer Eradication after Chemoimmunotherapy Is Associated with Profound Phenotypic Change of Intratumoral Myeloid Cells , 2011, The Journal of Immunology.

[20]  J. Prieto,et al.  Treatment of pancreatic cancer with an oncolytic adenovirus expressing interleukin-12 in Syrian hamsters. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  R. Cattaneo,et al.  An immunocompetent murine model for oncolysis with an armed and targeted measles virus. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  N. Gusani,et al.  Cytokine-secreting herpes viral mutants effectively treat tumor in a murine metastatic colorectal liver model by oncolytic and T-cell-dependent mechanisms , 2007, Cancer Gene Therapy.

[23]  E. Genden,et al.  Interleukin‐12 Expression Enhances Vesicular Stomatitis Virus Oncolytic Therapy in Murine Squamous Cell Carcinoma , 2007, The Laryngoscope.

[24]  P. Staeheli,et al.  RNA Polymerase II-Controlled Expression of Antigenomic RNA Enhances the Rescue Efficacies of Two Different Members of the Mononegavirales Independently of the Site of Viral Genome Replication , 2006, Journal of Virology.

[25]  C. James,et al.  Rescue and propagation of fully retargeted oncolytic measles viruses , 2005, Nature Biotechnology.

[26]  Claus Lindbjerg Andersen,et al.  Normalization of Real-Time Quantitative Reverse Transcription-PCR Data: A Model-Based Variance Estimation Approach to Identify Genes Suited for Normalization, Applied to Bladder and Colon Cancer Data Sets , 2004, Cancer Research.

[27]  S. Ha,et al.  IL-12 Priming during In Vitro Antigenic Stimulation Changes Properties of CD8 T Cells and Increases Generation of Effector and Memory Cells1 , 2004, The Journal of Immunology.

[28]  L. Mollet,et al.  A Molecularly Cloned Schwarz Strain of Measles Virus Vaccine Induces Strong Immune Responses in Macaques and Transgenic Mice , 2003, Journal of Virology.

[29]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[30]  D. Gerlier,et al.  Restriction of Measles Virus RNA Synthesis by a Mouse Host Cell Line: trans-Complementation by Polymerase Components or a Human Cellular Factor(s) , 2002, Journal of Virology.

[31]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[32]  A. Zlotnik,et al.  Chemokines: agents for the immunotherapy of cancer? , 2002, Nature Reviews Immunology.

[33]  R. Plemper,et al.  Single-Chain Antibody Displayed on a Recombinant Measles Virus Confers Entry through the Tumor-Associated Carcinoembryonic Antigen , 2001, Journal of Virology.

[34]  Mamoru Ito,et al.  Perforin‐dependent NK cell cytotoxicity is sufficient for anti‐metastatic effect of IL‐12 , 1999, European journal of immunology.

[35]  M. Billeter,et al.  Rescue of measles viruses from cloned DNA. , 1995, The EMBO journal.

[36]  L. Luistro,et al.  Antitumor and antimetastatic activity of interleukin 12 against murine tumors , 1993, The Journal of experimental medicine.

[37]  L. Roux,et al.  The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA , 1993, Journal of virology.

[38]  F. Podlaski,et al.  Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). , 1991, Journal of immunology.

[39]  P. Hand,et al.  Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. , 1991, Cancer research.

[40]  A. Schwarz.  Preliminary tests of a highly attenuated measles vaccine. , 1962, American journal of diseases of children.

[41]  S. Russell,et al.  Measles virus for cancer therapy. , 2009, Current topics in microbiology and immunology.

[42]  T. Town,et al.  Approaches to determine expression of inflammatory cytokines. , 2009, Methods in molecular biology.

[43]  R. Mulligan,et al.  Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo , 1997, Nature Biotechnology.